| Literature DB >> 29909776 |
Masato Yoshizawa1, Alexander Settle2, Meredith C Hermosura3, Lillian J Tuttle2, Nicolas Cetraro2, Courtney N Passow4, Suzanne E McGaugh4.
Abstract
BACKGROUND: An essential question in evolutionary biology is whether shifts in a set of polygenic behaviors share a genetic basis across species. Such a behavioral shift is seen in the cave-dwelling Mexican tetra, Astyanax mexicanus. Relative to surface-dwelling conspecifics, cavefish do not school (asocial), are hyperactive and sleepless, adhere to a particular vibration stimulus (imbalanced attention), behave repetitively, and show elevated stress hormone levels. Interestingly, these traits largely overlap with the core symptoms of human autism spectrum disorder (ASD), raising the possibility that these behavioral traits are underpinned by a similar set of genes (i.e. a repeatedly used suite of genes). RESULT: Here, we explored whether modification of ASD-risk genes underlies cavefish evolution. Transcriptomic analyses revealed that > 58.5% of 3152 cavefish orthologs to ASD-risk genes are significantly up- or down-regulated in the same direction as genes in postmortem brains from ASD patients. Enrichment tests suggest that ASD-risk gene orthologs in A. mexicanus have experienced more positive selection than other genes across the genome. Notably, these positively selected cavefish ASD-risk genes are enriched for pathways involved in gut function, inflammatory diseases, and lipid/energy metabolism, similar to symptoms that frequently coexist in ASD patients. Lastly, ASD drugs mitigated cavefish's ASD-like behaviors, implying shared aspects of neural processing.Entities:
Keywords: Adaptation; Astyanax mexicanus; Psychiatric disease; Systemic regulation; Vertebrate model; hapFLK
Mesh:
Year: 2018 PMID: 29909776 PMCID: PMC6004695 DOI: 10.1186/s12862-018-1199-9
Source DB: PubMed Journal: BMC Evol Biol ISSN: 1471-2148 Impact factor: 3.260
The enrichment of the expression shifts between surface fish and cavefish in ASD-risk genes
| Human ASD-risk genes | Cavefish genes | |||||
|---|---|---|---|---|---|---|
| Risk category | # of Listed Genes in | % (#) human ASD-risk genes with cavefish orthologs | % (#) of orthogroups that show significant age × morph interaction† | % (#) of orthogroups that show significant expression difference between morphs at 72 hpf† | % (#) of all paralogs that show significant age × morph interaction† | % (#) of all paralogs that show significant expression difference between morphs at 72 hpf† |
| Category 1 | 19 | 94.7% | 72.2% | 94.4% | 61.1% | 75.0% |
| Category 2 | 43 | 93.0% | 65.0% | 67.5% | 60.7% | 64.3% |
| Category 3 | 139 | 95.0% | 60.6% | 70.5% | 50.3% | 58.2% |
| Category 4 | 244 | 89.8% | 62.6% | 63.0% | 51.9% | 52.5% |
| Category S (not already included among Cat 1–4 genes) | 48 | 97.9% | 57.4% | 63.8% | 44.2% | 49.4% |
| Total | 493 | 92.5% | 62.1% | 66.9% | 53.8% | 54.6% |
| Bootstrapping score: mean ± 95% confidence interval | 48.0 ± 4.2% | 49.0 ± 4.4% | ||||
The 72 h post-fertilization (hpf) represents the stage in which fish have hatched, but have not yet developed a swim bladder and the jaw is underdeveloped, comparable to the late embryonic stage of mammals [111]. † P < 0.05 after Benjamini-Hochberg adjustment. Percentiles in the tables are from 9999-bootstrapped values. SF: surface fish. CF: Pachón cavefish. Hpf: hours post fertilization. We avoided testing the differences between morphs in each developmental time point (i.e. 10, 24 and 36 hpf) due to save statistical power. The number of genes are indicated in parentheses. See also Additional file 1 for each statistical test of age x morph and expression difference at 72 hpf
Direction of gene expression (up- or down-regulated) in this and previously published studies (cavefish compared with surface fish, and cases compared with controls)
| # orthologs of SFARI Gene that express differently (up or down) | Transcriptome from the cortices of ASD patients (Voineagu et al., 2011) | Transcriptomes from multiple tissues of ASD patients (review: Ansel et al., 2017) | Transcriptome from the cortices of ASD patients (Parikshak et al., 2016) | |
|---|---|---|---|---|
|
| 335 of 409† (81.9%) | 43‡ of 58 orthologs expressed differently between CF and SF | 51‡§ of 77 orthologs expressed differently between CF and SF | 2567‡ of 3442 orthologs expressed differently between CF and SF |
| 31 of 51‡ genes expressed in the same direction: | 27 of 45‡§ directionally expressed genes are in the same direction: | 1843 of 3152‡ directionally expressed genes are in the same direction: | ||
| BTBR Mouse (Hippocampus) | 30 of 493 (6.1%) | 2 of 65 orthologs expressed differently in BTBR mouse | 9§ of 105 orthologs expressed differently in BTBR mouse | 216 of 4042 orthologs expressed differently in BTBR mouse |
| 0 of 2 genes expressed in the same direction | 4 of 7§ directionally expressed genes are in the same direction | 109 of 216 directionally expressed genes are in the same direction | ||
| ASD patients (Blood) | 51 of 493 (10.3%) | 11 of 65 human genes expressed differently in ASD patient’s blood | 16§ of 107 human genes expressed differently in ASD patient’s blood | 485 of 4425 human genes expressed differently in ASD patient’s blood |
| 7 of 11 genes expressed in the same direction | 4 of 7§ directionally expressed genes are in the same direction | 179 of 485 directionally expressed genes are in the same direction | ||
| Neural cells derived from iPS cell of ASD patient | 95 of 493 | 18 of 65 of human genes expressed differently in neurons derived from iPS cells of ASD patients | 21§ of 107 human genes expressed differently in neurons derived from iPS cells of ASD patients | 527 of 4425 human genes expressed differently in neurons derived from iPS cells of ASD patients |
| 0 of 18 human genes expressed in the same direction | 1 of 16§ directionally expressed genes are in the same direction | 163 of 527 directionally expressed genes are in the same direction |
† 84 of 493 orthologs were not found in the Astyanax gene build at 2016 (Ensembl.org Assembly: AstMex102; Genebuild at Jul 2016)
‡ Some orthologs of human genes have multiple paralogs in A. mexianus (i.e. shank3a and shank3b)
§ We excluded genes that showed inconsistent expression directions between multiple reports (i.e. up-regulated in one paper but down-regulated in another [34])
Χ2 tests for differentially expressed genes against total genes between A. mexicanus and BTBR Mouse (a: Χ2 = 30.2, P = 1.17 × 10− 7; b: Χ2 = 31.3, P = 6.57 × 10− 8; and c: Χ2 = 1785.6, P < 1.0 × 10− 10), between A. mexicanus and patients’ blood (d: Χ2 = 14.9, P = 3.48 × 10− 4; e: Χ2 = 21.7, P = 9.40 × 10− 6; and f: Χ2 = 1445.5, P < 1.0 × 10− 10), and between A. mexicanus and patients’ iPS cells (g: Χ2 = 8.1, P = 0.0136; h: Χ2 = 16.3, P = 1.66 × 10− 4; and i: Χ2 = 1377.2, P < 1.0 × 10− 10). All of these tests have df = 1. P-values were multiplied by the number of the tests (Bonferroni correction)
Gene set enrichment analysis based on Fisher’s exact test with Yate’s continuity correction
| Divergence metrics | Comparisons | Significant ASD genes | Total ASD genes | Significant genes in genome | Total genes in genome | Yate’s Chi Square X2 | Degrees of freedom | Yate’s |
|---|---|---|---|---|---|---|---|---|
|
| Whole genome | 86 | 635a | 1648 | 22,710 | 34.557 | 1 | < 0.0001 |
Gene enrichment for ASD genes was based on comparisons between Choy surface (Choy) and Cave (Pachón). Calculations were performed using the chisq.test function in R
aNote that total ASD genes for hapFLK is lower than the total for orthologs and paralogs due to missing data
Fig. 1The congruency between quantitative trait loci and ASD-risk genes highlights potential genetic hubs for gene regulation. Linkage map constructed from 115 F2 hybrid progeny of a cross between a single surface fish female and a single male Pachón cavefish. The map includes 699 markers assembled into 25 linkage groups that collectively span 1835.5 cM. Colored bars represent approximate position of QTL for eye size, chemical (amino acid) sensing ability, taste bud number, VAB level, and the number of mechanosensory superficial neuromast at the eye orbit (EO SN) as indicated [74, 109]. Lens: lens size, Mel: melanophore number, Teeth: teeth number, Eye: eye size, Tbud: taste bud number, ONL: thickness in the outer nuclear layer of retina [110]. Each linkage group is annotated with genomic marker (right side) and anchored ASD-risk genes (left side). Blue characters in genomic markers are the ones that share the same genomic scaffold as the ASD-risk genes on the left side. Red characters in ASD-genes are the ones that show the signatures of divergence shown in Additional file 7. Other genes (at the left) are successfully anchored Category 1 and 2 SFARI Genes (Additional file 9, also Additional file 1)
Fig. 2Human drugs for ASD mitigated cavefish-type symptoms in F1 hybrid and cavefish. (a-e) Adherence to 40-Hz vibration stimulus. Vibration attraction behavior is represented by the square-rooted number of approaches during a 3-min assay. (f-j) Swimming distance (m per 24-h assay). (k-o) The changes in sleep duration (h per 24-h assay). Before and after treatment of drugs used for ASD patients—aripiprazole (a, f, k), risperidone (b, g, l), fluoxetine (c, h, m), clozapine (d, i, n), naltrexone (e, j, o)—were observed for 24 h each and plotted with means ± s.e.m. In these cases, there are significant shifts of cavefish behaviors after treatment towards the surface fish behaviors before treatment, except for the naltrexone treatments. Stars indicate the significant behavioral changes between before and after drug treatments (paired t-test adjusted by Bonferroni correction, ***: P < 0.001, **: P < 0.01, *: P < 0.05). Black line: surface fish, and orange line: cavefish. All statistics are available in Additional file 11. Black dashed lines in a-e indicate the threshold level of vibration attraction behavior (square-rooted number of approaches equals 2) [20]
PCR primers used in quantitative RT-PCR study
| Primer Name | Ensemble Gene ID | Forward Sequence | Reverse Sequence |
|---|---|---|---|
|
| ENSAMXG00000009680 | AGTATGACCCACGGCTAGAG | CGATCACATAATCACTGTAGGAGG |
|
| ENSAMXG00000004290 | CGAATTACACCAGCAGAAATCAG | CCTCAGTAGCTCCGAAAGAC |
|
| ENSAMXG00000006355 | AGAGTCACTGGATGTGATTCAC | TTCTTGGTTCAAGTCGATGATCTC |
|
| ENSAMXG00000020652 | AAATGAACACCAGGTTTCGAC | AGAAAGTGATGTCTGCTCCA |
|
| ENSAMXG00000017258 | GGCTGATGATTGAAACAGAGAC | CATGTCGTCTTCCATTTACTACC |
|
| ENSAMXG00000020522 | TATTACACGCGTATTTCAGGG | TAGACACAGATATCCACGAAGAG |
|
| ENSAMXG00000010994 | CGGGACTACTTGATTCTAACTCTG | TACAACTTCACCTTAAAGTTCGGG |
|
| ENSAMXG00000004964 | TCTTCACCTACATCTTCATCCTG | CCAAAGACACATCTACAATGAGG |
|
| ENSAMXG00000011344 | TTCACACCTCAGAAGAACGA | ACTGCATTCTCCATCTGGT |
|
| ENSAMXG00000018020 | TATCATTGAGGAGTCTGGAGAG | TGGGTCGGATTTCTTAATTGG |
|
| ENSAMXG00000007922 | CCATCAAGGGTGTTGGTAGG | TGCATAATGGTCACCACCC |
Drug information used in this study
| Drug Name | Commercial Name | Target | Application Method | References |
|---|---|---|---|---|
| Aripiprazole | Abilify | Partial agonist for the receptors of dopamine, serotonin and others | Bath (1–5 μM) | [ |
| Risperidone | Risperdal | Antagonist for the receptors of dopamine, serotonin and others | Bath (1–5 μM) | [ |
| Fluoxetine | Prozac | Selective serotonin reuptake inhibitor (SSRI) | Bath (1.0–28.5 μM) | [ |
| Clozapine | Clozaril | Antagonist for the receptors of dopamine, serotonin and others | Bath (0.1–12.5 μM) | [ |
| Naltrexone | Revia | Opiate antagonist | Injection (5–10 μg/g) | [ |